[ { "model_name":"abrocitinib 200 mg QD", "score":86.6, "EASI-50":86.6, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", "notes":"Combination therapy RCTs" }, { "model_name":"Upadacitinib", "score":85.6, "EASI-50":null, "Time":"Week 12", "EASI percent reduction":"85.6%", "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan", "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.16549", "notes":"Median percent reduction in EASI at week 12 with Upadacitinib 15 mg\/day plus topical corticosteroids." }, { "model_name":"upadacitinib 30 mg once daily (QD)", "score":83.6, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":83.6, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", "notes":"Monotherapy RCTs" }, { "model_name":"dupilumab 300 mg Q2W", "score":82.4, "EASI-50":82.4, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", "notes":"Combination therapy RCTs" }, { "model_name":"abrocitinib 100 mg QD", "score":79.7, "EASI-50":79.7, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", "notes":"Combination therapy RCTs" }, { "model_name":"Human", "score":79.2, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"79.2", "SITE [57]":"67.5", "MMSI [68]":"97.2", "OmniSpatial [23]":"92.63", "MindCube ∗ [69]":"94.55", "STARE [32]":"96.50", "CoreCognition [33]":"86.98", "SpatialViz [55]":"82.46", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"abrocitinib 200 mg QD", "score":74.6, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":74.6, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", "notes":"Monotherapy RCTs" }, { "model_name":"Upadacitinib", "score":73.6, "EASI-50":null, "Time":"Week 4", "EASI percent reduction":"73.6%", "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan", "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.16549", "notes":"Median percent reduction in EASI at week 4 with Upadacitinib 15 mg\/day plus topical corticosteroids." }, { "model_name":"upadacitinib 15 mg QD", "score":70.5, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":70.5, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", "notes":"Monotherapy RCTs" }, { "model_name":"Upadacitinib", "score":67.7, "EASI-50":null, "Time":"Week 12", "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":"67.7%", "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan", "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.16549", "notes":"Achievement rate of EASI 75 at week 12 with Upadacitinib 15 mg\/day plus topical corticosteroids." }, { "model_name":"dupilumab 300 mg every 2 weeks (Q2W)", "score":63.4, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":63.4, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", "notes":"Monotherapy RCTs" }, { "model_name":"Qwen3-8B-Instruct [65]", "score":57.9, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"57.90", "SITE [57]":"45.83", "MMSI [68]":"31.10", "OmniSpatial [23]":"45.73", "MindCube ∗ [69]":"29.42", "STARE [32]":"39.76", "CoreCognition [33]":"69.67", "SpatialViz [55]":"17.54 †", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"† indicates cases where generations were truncated due to overlong chains of thought, yielding no final answer; such instances are counted as incorrect, which depresses the score." }, { "model_name":"abrocitinib 100 mg QD", "score":56.7, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":56.7, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", "notes":"Monotherapy RCTs" }, { "model_name":"InternVL3.5-8B [56]", "score":56.05, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"56.05", "SITE [57]":"43.79", "MMSI [68]":"27.30", "OmniSpatial [23]":"46.71", "MindCube ∗ [69]":"42.50", "STARE [32]":"40.18", "CoreCognition [33]":"66.40", "SpatialViz [55]":"23.98", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"GPT-5-2025-08-07 [45]", "score":55.03, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"55.03", "SITE [57]":"61.88", "MMSI [68]":"41.80", "OmniSpatial [23]":"59.90", "MindCube ∗ [69]":"56.30", "STARE [32]":"54.59", "CoreCognition [33]":"84.37", "SpatialViz [55]":"51.27", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"Gemini-2.5-pro-2025-06 [52]", "score":53.57, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"53.57", "SITE [57]":"57.06", "MMSI [68]":"38.00", "OmniSpatial [23]":"55.38", "MindCube ∗ [69]":"57.60", "STARE [32]":"49.14", "CoreCognition [33]":"76.70", "SpatialViz [55]":"42.71", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"Upadacitinib", "score":51.6, "EASI-50":null, "Time":"Week 4", "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":"51.6%", "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan", "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.16549", "notes":"Achievement rate of EASI 75 at week 4 with Upadacitinib 15 mg\/day plus topical corticosteroids." }, { "model_name":"high dose hUCB-MSC", "score":50.0, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":50.0, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I\/IIa Studies", "source_url":"https:\/\/doi.org\/10.1002\/stem.2401", "notes":"Fifty-five percent of patients in high dose hUCB-MSC-treated group showed a 50% reduction in the EASI score." }, { "model_name":"EASI 50", "score":50.0, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":50.0, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study*", "source_url":"https:\/\/doi.org\/10.1111\/bjd.19457", "notes":"Meaningful percentage MIC regardless of baseline AD severity." }, { "model_name":"Seed-1.6-2025-06-15 [51]", "score":49.91, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"49.91", "SITE [57]":"54.61", "MMSI [68]":"38.30", "OmniSpatial [23]":"49.32", "MindCube ∗ [69]":"48.75", "STARE [32]":"46.06", "CoreCognition [33]":"77.17", "SpatialViz [55]":"34.58", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"GPT-5-mini-2025-08-07 [45]", "score":48.67, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"48.67", "SITE [57]":"52.47", "MMSI [68]":"34.10", "OmniSpatial [23]":"55.52", "MindCube ∗ [69]":"56.69", "STARE [32]":"52.51", "CoreCognition [33]":"77.77", "SpatialViz [55]":"44.66", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"Grok-4-2025-07-09 [62]", "score":47.92, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"47.92", "SITE [57]":"47.01", "MMSI [68]":"37.80", "OmniSpatial [23]":"46.84", "MindCube ∗ [69]":"63.56", "STARE [32]":"26.90", "CoreCognition [33]":"79.27", "SpatialViz [55]":"19.40 †", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"† indicates cases where generations were truncated due to overlong chains of thought, yielding no final answer; such instances are counted as incorrect, which depresses the score." }, { "model_name":"InternVL3-78B [79]", "score":47.55, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"47.55", "SITE [57]":"52.72", "MMSI [68]":"30.50", "OmniSpatial [23]":"50.95", "MindCube ∗ [69]":"49.52", "STARE [32]":"42.00", "CoreCognition [33]":"71.16", "SpatialViz [55]":"31.10", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"GPT-5-nano-2025-08-07 [45]", "score":43.22, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"43.22", "SITE [57]":"35.81", "MMSI [68]":"28.90", "OmniSpatial [23]":"47.81", "MindCube ∗ [69]":"41.48", "STARE [32]":"46.05", "CoreCognition [33]":"67.92", "SpatialViz [55]":"35.59", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"InternVL3-8B [79]", "score":42.14, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"42.14", "SITE [57]":"41.15", "MMSI [68]":"28.00", "OmniSpatial [23]":"46.25", "MindCube ∗ [69]":"41.54", "STARE [32]":"41.36", "CoreCognition [33]":"60.92", "SpatialViz [55]":"30.00", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"Qwen2.5-VL-72B-Instruct [1]", "score":35.77, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"35.77", "SITE [57]":"47.41", "MMSI [68]":"32.50", "OmniSpatial [23]":"47.81", "MindCube ∗ [69]":"42.40", "STARE [32]":"38.37", "CoreCognition [33]":"69.22", "SpatialViz [55]":"32.54", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"Random Choice", "score":34.0, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"34.00", "SITE [57]":"0.0", "MMSI [68]":"25.00", "OmniSpatial [23]":"24.98", "MindCube ∗ [69]":"32.35", "STARE [32]":"34.80", "CoreCognition [33]":"33.93", "SpatialViz [55]":"25.08", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"VSI random choice here is chance level(Frequency)." }, { "model_name":"Qwen2.5-VL-7B-Instruct [1]", "score":32.3, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"32.30", "SITE [57]":"37.64", "MMSI [68]":"26.80", "OmniSpatial [23]":"39.07", "MindCube ∗ [69]":"36.05", "STARE [32]":"35.03", "CoreCognition [33]":"62.16", "SpatialViz [55]":"26.78", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"Easi-CRISPR", "score":30.0, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":"30–60%", "specificity":null, "median EASI":null, "source_title":"Easi-CRISPR for creating knock-in and conditional knockout mouse models using long ssDNA donors", "source_url":"https:\/\/doi.org\/10.1038\/nprot.2017.153", "notes":"Typically 30-60% efficiency, reaching as high as 100% in some cases." }, { "model_name":"Qwen2.5-VL-3B-Instruct [1]", "score":27.0, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":"27.00", "SITE [57]":"33.14", "MMSI [68]":"28.60", "OmniSpatial [23]":"42.47", "MindCube ∗ [69]":"37.60", "STARE [32]":"37.83", "CoreCognition [33]":"60.19", "SpatialViz [55]":"21.86", "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":null, "source_title":"EASI", "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", "notes":"None" }, { "model_name":"EASI", "score":0.47, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":0.75, "median EASI":null, "source_title":"Development and Validation of a Tool to Improve Physician Identification of Elder Abuse: The Elder Abuse Suspicion Index (EASI)©", "source_url":"https:\/\/doi.org\/10.1080\/08946560801973168", "notes":"The EASI had an estimated sensitivity and specificity of 0.47 and 0.75" }, { "model_name":"placebo", "score":-1.3, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":-1.3, "source_title":"Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H4<\/sub>R‐antagonist (JNJ<\/scp>‐39758979) inJ<\/scp>apanese adults with moderate atopic dermatitis", "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.12726", "notes":"at week 6" }, { "model_name":"JNJ-39758979 300 mg", "score":-3.0, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":-3.0, "source_title":"Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H4<\/sub>R‐antagonist (JNJ<\/scp>‐39758979) inJ<\/scp>apanese adults with moderate atopic dermatitis", "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.12726", "notes":"at week 6" }, { "model_name":"JNJ-39758979 100 mg", "score":-3.7, "EASI-50":null, "Time":null, "EASI percent reduction":null, "EASI-50 response":null, "VSI [66]":null, "SITE [57]":null, "MMSI [68]":null, "OmniSpatial [23]":null, "MindCube ∗ [69]":null, "STARE [32]":null, "CoreCognition [33]":null, "SpatialViz [55]":null, "EASI 75 achievement rate":null, "EASI score reduction (%)":null, "percentage MIC":null, "efficiency":null, "specificity":null, "median EASI":-3.7, "source_title":"Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H4<\/sub>R‐antagonist (JNJ<\/scp>‐39758979) inJ<\/scp>apanese adults with moderate atopic dermatitis", "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.12726", "notes":"at week 6" } ]